CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for UMN Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

UMN Pharma Inc
4-2-3, Goshonoyumoto
Phone: +81 188927411p:+81 188927411 Akita-Shi, AKT  010-1415  Japan Fax: +81 455959845f:+81 455959845
This company is no longer actively traded on any major stock exchange.
Business Summary
UMN Pharma Inc. is a Japan-based biotechnology company mainly engaged in the biopharmaceuticals development business. The Company is engaged in the development, manufacturing and sales of biopharmaceuticals based on the baculovirus expression vector system (BEVS) manufacturing platform. The Company's pipelines include seasonal influenza vaccine UMN-0502, pandemic influenza vaccine UMN-0501, pandemic influenza vaccine UMN-0901 and norovirus/rotavirus vaccine UMN-2003.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201912/31/2018Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, President of Subsidiary, Representative Director TatsuyoshiHirano 57 8/1/2013
Director of Finance, Director HiroyukiHashimoto 48 3/1/2012 3/1/2012
Director of Clinical Development, Director FumihisaNakata 48 8/1/2011 8/1/2010

General Information
Number of Employees: 35 (As of 12/31/2018)
Outstanding Shares: 17,696,154 (As of 12/31/2019)
Shareholders: 11,113
Stock Exchange: TYO
Fax Number: +81 455959845


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023